IMPLEMENTATION THE TERMINOLOGY OF METABOLIC-ASSOCIATED FATTY LIVER DISEASE INTO MEDICINE AND ITS ROLE TO DEVELOP DIAGNOSTIC AND TREATMENT MEASURES
Keywords:
metabolic liver disease, fatty liver disease, steatohepatitis, diagnosisAbstract
Metabolically associated fatty liver disease (MAFLD) is a widespread chronic condition characterized by a high degree of fat accumulation in the liver due to metabolic dysfunction. Over the past 10 years, the rate of MAFLD diagnosis in most regions of the world has exceeded 20%, and it can be noted that this figure is dynamically increasing. The replacement of the term NAFLD with MAFLD has largely created convenience for both patients and specialists in the field. The non-use of the word 'alcohol' in the diagnosis has ensured a correct perception of the disease, without negatively impacting the mental state of patients, while the absence of contraindications for diagnosing viral, autoimmune hepatitis, and alcoholic hepatitis in MAFLD has contributed to a broad approach.
References
Аляви А.Л., Собирова Г.Н., Абдуллаев А.О., Шадманова Д.А. Пути преодоления трудностей в диагностике неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2023;(10):175-181. https://doi.org/10.31146/1682-8658-ecg-218-10-175-181
Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the diagnosis and Management of Nonalcoholic Fatty Liver Disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. (2022) 28:528–62. doi: 10.1016/j.eprac.2022.03.010
Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, et al. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab. (2017) 19:1630–4. doi: 10.1111/dom.12973
Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. (2020) 158:1999–2014. doi: 10.1053/j.gastro.2019.11.312 21. Day CPJames OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. (1998) 114:842–5. doi: 10.1016/S0016-5085(98)70599-2
Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from "two hit theory" to "multiple hit model". World J Gastroenterol. (2018) 24:2974–83. doi: 10.3748/wjg.v24.i27.2974
Hamraev A.A., Yuldasheva D.Kh. “Prevalence of non-alcoholic fatty liver disease, clinical and laboratory markers”, Central Asian Journal of Medicine, 2022, bet. 112–123.
Liu Z, Suo C, Shi O, Lin C, Zhao R, Yuan H, et al. The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease–related genetic variants. Clin Gastroenterol Hepatol. (2022) 20:e855–75. doi: 10.1016/j.cgh.2020.12.033
Spearman CW, Afihene M, Betiku O, Bobat B, Cunha L, Kassianides C, et al. Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol. (2021) 6:1036–46. doi: 10.1016/S2468-1253(21)00275
Zhang H-J, Wang Y-Y, Chen C, Lu Y-L, Wang N-J. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999–2016. Chin Med J. (2021) 134:1593–601. doi: 10.1097/CM9.0000000000001513
Xian Y-X, Weng J-P, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. (2021) 134:8–19. doi: 10.1097/CM9.0000000000001263
Xudoykulova F. V. va boshq. THE STRUCTURE, AGE FEATURES, AND FUNCTIONS OF HORMONES //PEDAGOG. – 2023. – Т. 1. – №. 5. – С. 681-688
